Funder
National Natural Science Foundation of China
Reference31 articles.
1. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial;Agarwal;Lancet,2019
2. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient;Ash;Kidney Int.,2015
3. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis;Bushinsky;Am. J. Nephrol.,2016
4. Hyperkalemia as an independent risk factor for death while under mechanical ventilation among children hospitalized with diarrhea in Bangladesh;Chowdhury;Global Pediatric Health,2018
5. Patiromer for the treatment of hyperkalemia;Colbert;Expet Rev. Clin. Pharmacol.,2020
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献